

Peptide-based probes for protein N-Methyltransferases Zhang, Y.

Citation

Zhang, Y. (2022, June 2). *Peptide-based probes for protein N-Methyltransferases*. Retrieved from https://hdl.handle.net/1887/3307258

Version:	Publisher's Version		
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden		
Downloaded from:	https://hdl.handle.net/1887/3307258		

Note: To cite this publication please use the final published version (if applicable).

Supplementary materials for Chapter 2-5 Appendix I - IV

Appendix I Supplementary materials for Chapter 2

High resolution Mass Spectrometry (HRMS) data for compounds 1-6:

- 1: HRMS (m/z): $[M+H]^+$ calculated for $C_{35}H_{60}N_{17}O_{11}^+$, 894.4653, found 894.4670.
- 2: HRMS (m/z): $[M+H]^+$ calculated for $C_{37}H_{62}N_{17}O_{12}^+$, 936.4758, found 936.4782.
- 3: HRMS (m/z): $[M+H]^+$ calculated for $C_{41}H_{72}N_{19}O_{12}^{+}$, 1022.5602, found 1022.5621.
- 4: HRMS (m/z): $[M+H]^+$ calculated for $C_{43}H_{74}N_{19}O_{13}^+$, 1064.5708, found 1064.5730.
- 5: HRMS (m/z): $[M+H]^+$ calculated for $C_{25}H_{48}N_{12}O_8^+$, 645.3796, found 645.3795.
- 6: HRMS (m/z): $[M+H]^+$ calculated for $C_{31}H_{60}N_{14}O_9^+$, 773.4746, found 773.4759.



Figure S1a. IC₅₀ curves for compounds 1-4 against PRMT1



Figure S1b. IC_{50} curves for compounds 1-4 against PRMT6











Appendix II Supplementary materials for Chapter 3

High Resolution Mass Spectrometry data and purified yields of compounds 1-14

Table S1. High Resolution Mass Spectrometry data and purified yields ofcompounds 1-14

Compound	Chemical formula	Calculated Mass	Found	Yield
1	$C_{201}H_{347}N_{74}O_{55}{}^{3+}$	1559.2205	1559.2210	11%
2	$C_{203}H_{350}N_{74}O_{56}{}^{4+}$	1180.1698	1180.1703	8%
3	$C_{98}H_{170}N_{36}O_{26}{}^{2+}$	1134.1555	1134.1544	23%
4	$C_{100}H_{172}N_{36}O_{27}{}^{2+}$	1155.1608	1155.1606	26%
5	$C_{81}H_{141}N_{29}O_{24}^{2+}$	952.0297	952.0274	40%
6	$C_{83}H_{143}N_{19}O_{13}{}^{2+}$	973.0349	973.0330	39%
7	$C_{60}H_{103}N_{22}O_{16}^{+}$	1387.7922	1387.7912	47%
8	$C_{62}H_{105}N_{22}O_{17}^+$	1429.8082	1429.8052	41%
9	$C_{54}H_{93}N_{20}O_{13}{}^+$	1229.7231	1229.7223	50%
10	$C_{56}H_{95}N_{20}O_{14}^{+}$	1271.7336	1271.7340	50%
11	$C_{45}H_{76}N_{17}O_{11}{}^+$	1030.5910	1030.5907	51%
12	$C_{47}H_{78}N_{17}O_{12}{}^+$	1072.6070	1072.6012	50%
13	$C_{36}H_{60}N_{15}O_9^+$	846.4698	846.4697	53%
14	$C_{38}H_{62}N_{15}O_{10}{}^+$	888.4804	888.4812	55%

HPLC traces of compounds 1-14

HPLC chromatograms of compounds 1-4 were obtained by analytical RP-HPLC using a Phenomenex Kinetex C18 column ($250 \times 4.6 \text{ mm}$, 5 µm particle size) with UV detection at 214 nm. The following solvent system, at a flow rate of 0.7 mL/ min, was used: solvent A, 0.1 % formic acid in water; solvent B, methanol. Gradient elution was as follows: 95:5 (A/B) for 5 min, 95:5 to 50:50 (A/B) over 15 min, then reversion back to 95:5 (A/B) over 1 min, 95:5 (A/B) for 4 min.

HPLC chromatograms of compounds 5-14 were obtained by LCMS using a Shimadzu Shim-Pack GIST-AQ C18 column (3.0 x 150 mm, 3 μ m particle size) with UV detection at 214 nm. The following solvent system, at a flow rate of 0.5 mL/min, was used: solvent A, 0.1 % formic acid in water; solvent B, acetonitrile. Gradient elution was as follows: 95:5 (A/B) for 2 min, 95:5 to 0:100 (A/B) over 23 min, 0:100 (A/B) for 1 min, then reversion back to 95:5 (A/B) over 1 min, 95:5 (A/B) for 3 min.







IC₅₀ curves for compounds 5-14 and SAH

Д



Comparative table of IC₅₀ values and Ki values for compounds 5-14 and SAH

 IC_{50} values were determined as described in the experimental section. Briefly, normalized luminescence data from the activity assay was plotted as a function of inhibitor concentration and analyzed using the following equation:

$$Y = \frac{100}{(1+10^{((logIC50-X)\times Hill Slope}))}$$

Where Y = percentage activity, X = the logarithmic concentration of the inhibitors, Hill Slope= slope factor or Hill coefficient. The IC_{50} value was determined by the half maximal inhibitory concentration. The IC_{50} values measured for SAH, which served as a reference compound, are similar to those reported.

The K₁ values were determined using the same normalized luminescence data from the activity assay using the following equation:

$$Y = Vo * (1 - \frac{\left(Et + X + \left(Ki * \left(1 + \left(\frac{S}{Km}\right)\right)\right)\right) - \sqrt{((Et + X + \left(Ki * \left(1 + \left(\frac{S}{Km}\right)\right)\right))^2 - 4 * Et * X)}}{(2 * Et)})$$

Where Y = percentage activity, X = Concentration of inhibitor, Et = Enzyme concentration in micromolar, KM: Michealis-Menten constant of enzyme, KI: Dissociation constant of inhibitor in micromolar. Equation 9.6, in R.A. Copeland, Enzymes, 2nd edition, Wiley, 2001.

The enzyme concentration was fixed at 0.2 μ M and the substrate concentration was 12 μ M for the PABP1 peptide, which is equal to its KM value.

Compound		CARM1 Inhibition (µM) ^a		
Compound		IC ₅₀	KI	
SAH		0.756 ± 0.089	0.391 ± 0.040	
5	H3 ¹⁰⁻²⁵	0.290 ± 0.015	0.096 ± 0.009	
6	H3 ¹⁰⁻²⁵ (K ¹⁸ Ac)	0.155 ± 0.007	0.028 ± 0.004	
7	H3 ¹³⁻²²	0.121 ± 0.007	0.020 ± 0.002	
8	H3 ¹³⁻²² (K ¹⁸ Ac)	0.155 ± 0.012	0.030 ± 0.005	
9	H3 ¹⁴⁻²¹	0.287 ± 0.034	0.137 ± 0.018	
10	H3 ¹⁴⁻²¹ (K ¹⁸ Ac)	0.211 ± 0.023	0.066 ± 0.011	
11	H3 ¹⁵⁻²⁰	0.143 ± 0.014	0.036 ± 0.005	
12	H3 ¹⁵⁻²⁰ (K ¹⁸ Ac)	0.072 ± 0.008	0.001 ± 0.002	
13	H3 ¹⁶⁻¹⁹	0.346 ± 0.031	0.130 ± 0.017	
14	H3 ¹⁶⁻¹⁹ (K ¹⁸ Ac)	0.699 ± 0.081	0.320 ± 0.051	

Table S2. IC₅₀ values and Ki values for compounds 5-14

^a IC₅₀ and KI values reported in μ M from duplicate data obtained from a minimum of 7 different concentrations ± standard error of the mean (s.e.m.).

Supplemental table and figures for structural studies

Table S3. X-ray data collection and refinement statistics for mmCARM1 complexes with H313-31 peptidomimetics 3 and 4

PDB ID		70KP	70\$4	
TS Mimic		H313-31 K18Ac	H313-31 K18	
	Bosolution (Å)	46.11-2.20 (2.25-	45.76-2.54 (2.62-	
	Resolution (A)	2.20)	2.54)	
	space group	P21212	P21212	
	cell	74.91 99.58 208.07	74.37 98.61 206.61	
	Total reflections	406216 (16351)	315674 (22239)	
	Unique reflections	77281 (4317)	49843 (4042)	
	Rmerge	0.092 (0.693)	0.129 (2.284)	
Data processing	Rmeas	0.101 (0.809)	0.140 (2.501)	
Data processing	Rpim	0.040 (0.406)	0.055 (0.996)	
	Ι/σΙ	9.3 (1.5)	8.6 (0.6)	
	CC1/2	0.998 (0.690)	0.999 (0.475)	
	Completeness (%)	97.1 (93.7)	97.9 (87.4)	
	Multiplicity	5.3 (3.8)	6.3 (5.5)	
	Wilson B (Å ²)	35.2	63.5	
	Resolution limit for $U/\sigma(1) > 2 O(A)$	2.36	2.96	
	1//0 (1) ~ 2.0 (A)	45 37 _ 7 7 (7 78 -	45 76 - 2 542 (2 632 -	
	Resolution (Å)	2.2)	2.54)	
	Rwork (%)	21.08 (31.08)	0.71 (35.19)	
	Rfree (%	25.45 (34.88)	25.94 (36.78)	
Refinement	Number of non-hy-	12185	11675	
	macromolecules	11589	11504	
	ligands	297	266	
	solvent	425	21	
	RMS(bonds)	0.003	0.003	
	RMS(angles)	0.59	0.54	
Validation	Ramachandran fa- vored (%)	95.64	95.49	
	Ramachandran out- liers (%)	0.00	0.00	
	Rotamer outliers (%)	0.32	2.00	
	Average B-factor	47.62	64.83	

Statistics for the highest-resolution shell are shown in parentheses. The resolution limits for I/ σ (I) > 2 are reported.



Figure S1. Structure of transition state mimic overlaid with isolated peptide in presence of SFG. (A) H3¹³⁻³¹ K¹⁸ peptidomimetic 3 in complex with mmCARM1 (green cartoon and blue sticks, PDB code 7OS4) superimposed with structure of SFG-H3R17 bound to hs-CARM1 (gray cartoon/sticks, PDB code 5DX0). (B) Close-up around the SFG binding site. For clarity, the N-terminal helices of mmCARM1 and hsCARM1 are not shown.



Figure S2. Superimposition of $H3^{13-31}(Lys^{18}NH_2)$ and $H3^{13-31}(Lys^{18}Ac)$ complexes with mmCARM1 (only local view of monomer A shown). (A) Superposition of $H3^{13-31}(Lys^{18}NH_2)$ (blue sticks) and $H3^{13-31}(Lys^{18}Ac)$ (green sticks) bound to mmCARM1 (gray/green cartoon) (monomer A), PDB codes 7OS4 and 7OKP respectively. (B) Close-up view of recognition mode for $H3^{13-31}(Lys^{18}NH_2)$ and $H3^{13-31}(Lys^{18}Ac)$.

Appendix III Supplementary materials for Chapter 4

100,000)				 Max Int	tensity : 5
1:d3ADMA-F	PABP1 623.7500:	>210.9500(+) CE	28.0	Time 0.505 Scane 1 Intell.	
1:d3ADMA-F	PABP1-623 7500:	>140-0000(+) CE	-45.0		
Trades abrills of		1.0.0000(.) 02			
1:d3ADMA-F	PABP1 623.7500	>282.0000(+) CE	19.0	8	
				d d d d d	
				A	
				······································	
				·····	
					X
				*	

LC-MS traces of analyte and internal standard

Figure S1. LC-MS/MS traces of PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-d₆-aDMA (internal standard). MS method: 0.5-4.5 min; retention time 4.101 min, Q1 mass detection; 623.75; Q3 mass detection: 282.00, 210.95, 140.00.



Figure S2. LC-MS/MS traces of PABP1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰-aDMA (methylated product). MS method: 0.5-4.5 min; retention time 4.101 min, Q1 mass detection; 620.85; Q3 mass detection: 282.00, 211.00, 140.00.





Figure S3. A. EC₅₀ curve for CARM1, EC₅₀ = 11.68 ± 0.33 ng/µL. B. Michaelis-Menten Plot for K_M value determination of PABP1⁴⁵⁶⁻⁴⁶⁶, K_{M, PABP1 456-466} = 12.03 ± 2.28 µM. C. Michaelis-Menten Plot and Lineweaver Burk plot (D) for K_M value determination of AdoMet, K_{M, AdoMet} = 5.46 ± 0.01 µM.





Figure S4. IC_{50} curves of inhibitors 1-9. Blue curves represent the measurements obtained using the MRM LC-MS assay and red curves correspond to measurements obtained using commercially available the ELISA assay kit. The ELISA assay based IC_{50} values for compounds 1, 5-9 presented in Table 3 of the manuscript are taken from our previously published work and the corresponding inhibition curves can be found there (refs 27 and 20).

HPLC and High Resolution Mass Spectrometry data for PABP1⁴⁵⁶⁻⁴⁶⁶ peptides

High Resolution Mass Spectrometry (HRMS)

PABP1⁴⁵⁶⁻⁴⁶⁶ (m/z):

 $[M+H]^+$ calculated for $C_{55}H_{86}N_{15}O_{14}S^+$, 1212.6199, found 1212.6206.

PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aDMA (m/z):

 $[M+H]^+$ calculated for $C_{57}H_{90}N_{15}O_{14}S^+$, 1240.6512, found 1240.6516.

PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-d₆-aDMA (m/z):

 $[M+H]^{+}$ calculated for $C_{57}H_{84}D_6N_{15}O_{14}S^{+}$, 1246.6889, found 1246.6894



NMR Data of Fmoc-d₆-aDMA-OH

¹H NMR (500 MHz, CDCl₃)



Appendix

¹³C NMR (126 MHz, CDCl₃)





Appendix IV Supplementary materials for Chapter 5



Reprogrammed mRNA display protocol

Figure S1. Library enrichment by binding to NNMT plotted across all selection rounds (log scale on Y-axis), showing binding against both immobilised NNMT ('positive', blue/ light blue plus symbol) and against the immobilisation medium alone ('negative', or-ange/red cross symbol) for both the L- and D-tyrosine initiated libraries (respectively).



Figure S2. Sequence alignment of the L-tyrosine library (left) and D-tyrosine library (right). Colors indicate the properties of the respective amino acids. In both libraries hydrophobic (green) and positively charged (blue) amino acids are enriched.



Figure S3. HPLC purity traces for peptides 1-6 over 12 minutes (5-100% acetonitrile).



Figure S4. HPLC purity traces for peptides 7-12 over 12 minutes (5-100% acetonitrile).



Figure S5. HPLC purity traces for peptides 13-17 over 12 minutes (5-100% acetonitrile).

 IC_{50} curves



Figure S6. IC₅₀ curves for peptides 1-6 against hNNMT. Data is based on triplicate data of at least 10 different concentrations



Figure S7. IC_{50} curves for peptides 7-12 against hNNMT. Data is based on triplicate data of at least 10 different concentrations



Figure S8. IC_{50} curves for peptides 13-17 against hNNMT. Data is based on triplicate data of at least 10 different concentrations



юд µм Figure S8. IC₅₀ curves for peptides 13-17 against hNNMT. Data is based on triplicate

data of at least 10 different concentrations

 Δ



Figure S9. IC₅₀ curves for compounds X and Y and peptides 2-6 and 11 against hNNMT. Compounds were tested using normal conditions (substrates at their K_M value), or in the presence of 10-fold higher concentration of either nicotinamide (NA) or Sadenosyl-L-methionine (SAM). Data is based on duplicate data of at 8 different concentrations.



Figure S10. IC_{50} curves for peptides 12-13 and 15-17 against hNNMT. Peptides were tested using normal conditions (substrates at their K_M value), or in the presence of 10-fold higher concentration of either nicotinamide (NA) or S-adenosyl-L-methionine (SAM). Data is based on duplicate data of at 8 different concentrations.

Appendix





Figure S11. V_{max} and K_M values for NNMT and SAM respectively after treatment of varying concentrations of compound Y, 4 or 13. The change in K_M observed for SAM after treatment with compound Y supports competitive inhibition. The unchanged K_M and changing V_{max} observed for compounds 4 and 13 supports the non-competitive or allosteric mode of inhibition for the cyclic peptides.

Curriculum vitae

Yurui Zhang was born on 28 November 1991 in Datong, China. He started a bachelor's program in pharmaceutic science at Hebei medical University. Since 2011, he started his internship in the laboratory of Prof. Caiqing Yang, studying the preparation of Oleanolic Acid Co-crystals and analysis. After spending two years on bench work, he obtained a bachelor's degree (with distinction). Later, he was enrolled in Peking Union Medical College of TsingHua University in 2014. He conducted his scientific research under Prof. dr. Wenqing Xu, studying in radio protection and radio therapy in vivo and in vitro. In 2017, he was granted his Ph.D. studies from China Scholarship Council (CSC). He subsequently joins the Martin group under the supervision of Prof. dr. Nathaniel I. Martin and Dr. Matthijs J. van Haren. Most of his Ph.D. work is presented in this thesis.

List of Publications

Zhang, Y., van Haren, M.J., Marechal, N., Troffer-Charlier, N., Cura, V., Cavarelli, J., Martin, N.I. A Direct Assay for Measuring Activity and Inhibition of Coactivator Associated Arginine Methyltransferase 1. Biochemistry (Accepted in press)

Zhang, Y., Marechal, N., van Haren, M.J., Troffer-Charlier, N., Cura, V., Cavarelli, J., Martin, N.I. Structural studies provide new insights into the role of lysine acetylation on substrate recognition by CARM1 and inform the design of potent peptidomimetic inhibitors. ChemBioChem. (2021)

van Haren, M.J., Zhang, Y., Thijssen, V., Buijs, N., Gao, Y., Mateuszuk, L., Fedak, F.A., Kij, A., Campagna, R., Sartini, D., Emanuelli, M., Chlopicki, S., Jongkees, S.A.K., Martin, N.I. Macrocyclic Peptides as Allosteric Inhibitors of Nicotinamide N-Methyltransferase (NNMT). RSC Chemical Biology. (2021)

Gao, Y., van Haren, M.J., Buijs, N., Innocenti, P., Zhang, Y., Sartini, D., Campagna, R., Emanuelli, M., Parsons, R.B., Jespers, W., Gutiérrez-de-Terán, H., van Westen, G., Martin, N.I. Potent inhibition of nicotinamide N-methyltransferase by alkene linked bisubstrate mimics bearing electron deficient aromatics. Journal of Medicinal Chemistry. (2021)

Zhang, Y., van Haren, M.J., Martin, N.I. Peptidic transition state analogues as PRMT inhibitors. Methods. (2020)

Zhang, Y., Wang, J., Li, Y., Meng, Y., Zhang, Y., Yang, F., Xu, W. Design and Synthesis a Mitochondria-Targeted Dihydronicotinamide as Radioprotector. Free Radical Biology & Medicine. (2019)

Zhang, Y., Li, Y., Wang, J., Li, Wang, H., Wang, H., Kang, X., Xu, W. Synthesis and characterization of a rosmarinic acid derivative that targets mitochondria and protects against radiation-induced damage in vitro. Radiation Research. (2017)

Zhang Y, Wang, J., Li, Y., Wang, F., Yang, F., Xu, W. Synthesis and Radioprotective Activity of Mitochondria Targeted Dihydropyridines. International Journal of Molecular Science. (2017)

Liu, Y., Zhang, C., Zhang, H., Li, M., Yuan, J., Zhang, Y., Zhou, J., Guo, H., Zhao, L., Du, Y., Wang, L., Ren, L. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis. European Journal of Medicinal Chemistry. (2015)